Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Laurens van der Meer

Research Associate
Breaking therapy resistance in IKZF1 deleted Acute Lymphoblastic Leukemia
Based on the genomic characterization of acute lymphoblastic leukemia (ALL) we can predict a poor outcome, but changing outcome remains a challenge.
Phone -
Email -

We aim to understand how genetic factors associated with a poor prognosis, such as deletions of IKZF1, dictate tumor cell behavior and drive therapy resistance. Moreover, we use reverse genetic screens to identify pathways that are essential for the resistance phenotype aimed at designing combination therapies that either prevent or cure relapse.

  • Histone deacetylase inhibition sensitizes p53-deficient B-cell precursor acute lymphoblastic leukemia to chemotherapy

    • dec. 2023
    • Willem P J, Cox, et al
    • Haematologica
  • Reversal of IKZF1-induced glucocorticoid resistance by dual targeting of AKT and ERK signaling pathways

    • sep. 2022
    • Miriam, Butler, et al
    • Frontiers in Oncology
  • BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway

    • dec. 2021
    • Miriam, Butler, et al
    • Blood
  • Amino Acid Depletion Therapies

    • jun. 2021
    • Miriam, Butler, et al
    • Trends in endocrinology and metabolism: TEM
  • Tumor suppressors BTG1 and BTG2

    • mei 2019
    • Laurensia, Yuniati, et al
    • Journal of Cellular Physiology
View all publications